FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review

• FDA accepted Teva’s NDA for ecopipam to treat pediatric Tourette syndrome, granting priority review.
• PDUFA action date set for late Q1 2027.
• Ecopipam is a first-in-class selective D1 receptor antagonist with orphan drug designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190830OMX_____CNEWS_EN_GNW1001258273_en) on August 19, 2026, and is solely responsible for the information contained therein.